PATENT CLAIM ANALYSIS

Application Number: 16188489
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-06
Patent Classification: ["424", "001490"]

Abstract:
The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.

Claim (Index 36):
A pharmaceutical composition comprising the immunoglobulin molecule according to  claim 1 , and a pharmaceutical acceptable carrier.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 98.0
- Lexical Diversity: 1.2
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15207836', '15645442', '15337964', '15750982', '14348918']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7229316280625688
- 35 USC 102 Novelty (BERT): 0.684915047361141
- Combined Prediction Score: 0.7191299699924261
- Mean Citation Score: 495.281058
- Max Citation Score: 728.73364
- Similarity Product: 664.2899525022649

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test